Tyra Biosciences, (id:7937 TYRA)

15.83 USD

Opening hours: 09:30 - 16:00 (Eastern Standard Time: 11/24/2024 12:46:12 PM)

Exchange closed, opens in 20 hours 43 minutes

• 1 day
• 1 week
• 1 month
• 6 months
• 1 year
• All

About Tyra Biosciences,

Market Capitalization 801.05M

Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is TYRA-300, which is in Phase 1/2 clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, thanatophoric dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in Phase 1 clinical trial for bile duct and solid tumors; and TYRA-430 for the treatment of hepatocellular carcinoma. The company was incorporated in 2018 and is headquartered in Carlsbad, California.